乙酰半胱氨酸(Acetylcysteine) - 药物靶点：Free radicals_在研适应症：支气管炎，嵌甲，对乙酰氨基酚过量_专利_临床

概要

基本信息

药物类型

小分子化药

别名

(2R)-2-acetylamino-3-sulfanylpropanoic acid、(R)-2-acetylamino-3-mercaptopropanoic acid、(R)-mercapturic acid

+ [45]

靶点

Free radicals

作用方式

抑制剂

作用机制

自由基抑制剂

治疗领域

免疫系统疾病感染遗传病与畸形+ [7]

在研适应症

支气管炎嵌甲对乙酰氨基酚过量+ [12]

非在研适应症

急性支气管炎药物性肝损伤普通感冒+ [6]

原研机构

Apothecon LLC

在研机构

Zambon Switzerland Ltd.

精鼎医药研究开发（上海）有限公司Sannova KK

+ [6]

非在研机构

Zambon SpARxKinetix, Inc.

Galephar Pharmaceutical Research, Inc.

+ [4]

权益机构

浙江医学科技开发有限公司RxKinetix, Inc.

Zambon Group SpA

+ [3]

最高研发阶段批准上市

首次获批日期

美国 (1963-09-14),

药物性肝损伤肝损伤

最高研发阶段(中国)批准上市

特殊审评孤儿药 (美国)、孤儿药 (欧盟)

登录后查看时间轴

结构/序列

分子式C5H9NO3S

InChIKeyPWKSKIMOESPYIA-BYPYZUCNSA-N

CAS号616-91-1

关联

903

项与乙酰半胱氨酸相关的临床试验

NCT04520139

/ Not yet recruiting临床1/2期IIT

Phase I Dose-Escalating and Phase II Dose-Expansion Study of N-Acetyl-Cysteine (NAC) Administration to Ovarian Cancer Patients Receiving Platinum-Based Therapy (PBT) for the Mitigation of Chemotherapy-Related Cognitive Impairment (CRCI)

This is a phase I, dose-escalation and phase II dose-expansion clinical trial determining the maximum tolerated dose (MTD) and safety and tolerability of adding N-Acetyl-Cysteine (NAC) to ovarian cancer patients who are receiving a platinum-based therapy (PBT). This study will investigate whether NAC will mitigate chemotherapy-related cognitive impairment (CRCI).

开始日期2025-12-01

申办/合作机构

University of California, Irvine

[+1]

NCT04381897

/ Not yet recruiting临床2期IIT

Use of N-Acetylcysteine (NAC) in the Treatment of Repetitive Behaviors (RB) and Self-Injurious Behaviors (SIB) in Cornelia de Lange Syndrome: A Randomized Double-Blind Placebo-Controlled Pilot Study

This research project is a randomized cross-over pilot trial which aims to test the efficacy of N-acetylcysteine (NAC) for the treatment of Repetitive Behaviors (RB) and self-injurious behavior (SIB) in patients with Cornelia de Lange Syndrome (CdLs).
NAC is a known anti-oxidative stress and neuroprotective agent, which has been shown to decrease the occurrence of SIB such as skin picking. NAC has also shown partial response in trials for compulsive behaviors in Obsessive Compulsive Disorder (OCD) and related disorders in autism.
Cornelia de Lange syndrome (CdLS) is a genetic disorder with autistic features, including RBs and SIB. In this randomized clinical trial, participants with CdLS will be blindly assigned one of two possible treatment arms: 1) placebo (8 weeks) and NAC (8 weeks); or 2) NAC (8 weeks) and placebo (8 weeks), with an intermediate 2-week washout period.

开始日期2025-10-01

申办/合作机构

The Johns Hopkins University

NCT06956482

/ Not yet recruiting临床3期IIT

PROlonged Corticosteroid Treatment or N-ACetylcysteine for Severe Alcoholic Hepatitis

Only patients suffering from a severe form of alcoholic hepatitis (Maddrey's discriminant function greater than 32) require medical treatment. Oral prednisolone for 28 days is the only treatment which has been proven to improve short-term survival over placebo in patients with severe alcoholic hepatitis. However, prednisolone alone cannot be regarded as an ideal treatment because some patients still have a bad outcome despite being treated with corticosteroids. Response to treatment can be predicted by the Lille score, a simple tool that is calculated after 7 days of prednisolone course. The ideal binary cut-off of the Lille is 0.45, responders having a Lille score < 0.45 and non-responders having a Lille score ≥0.45. In terms of treatment management, approximately 30% of patients with severe alcoholic hepatitis do not take benefit from prednisolone and are classified as null responders by a Lille score greater than 0.56. In them, there is a consensus for stopping prednisolone after a 7-day course of treatment (Lille score is calculated after 7 days) while patients with a Lille score <0.56 continue treatment for a total of 30 days.
Numerous trials have attempted to test the impact of other strategies in association with prednisolone, but none of them has shown an improvement in survival (primary endpoint) as compared to prednisolone alone. These strategies include for instance pentoxifylline, amoxicillin-clavulanic acid and enteral nutrition.
Because oxidative stress is a major driver of liver injury during alcohol-related liver disease, antioxidants, especially N-acetylcysteine, have been tested for many years to treat alcoholic hepatitis. N-acetylcysteine alone does not seem to bring a survival benefit over placebo while it may improve outcome when combined to prednisolone.
Historically in severe alcoholic hepatitis, treatment is only given for one month. However, a significant proportion of patients still disclose impaired hepatic function after treatment has been stopped (e.g. 50% of patients still have a MELD score ≥17 after 60 days in). It is thus tempting to hypothesize that a proportion of patients will recover slowly and may take benefit from a prolonged treatment. Such strategy has been proposed in some old studies with relatively limited sample size but never tested with a rigorous approach.
In the present study, for the first time in alcoholic hepatitis, we will take into account the recent recommendations of international experts by choosing an innovative primary endpoint that does not only include mortality and evaluate this endpoint at the preferred timepoint of 90 days.
After more than 30 years of negative trials in severe alcoholic hepatitis, the present study is aimed to evaluate two important new strategies to decrease both mortality and liver impairment.

开始日期2025-10-01

申办/合作机构-

100 项与乙酰半胱氨酸相关的临床结果

登录后查看更多信息

100 项与乙酰半胱氨酸相关的转化医学

登录后查看更多信息

100 项与乙酰半胱氨酸相关的专利（医药）

登录后查看更多信息

38,338

项与乙酰半胱氨酸相关的文献（医药）

2025-12-31·Cell Adhesion & Migration

N-Acetylcysteine relieving hydrogen peroxide-induced damage in granulosa cells of sheep

Article

作者: Huo, Shengdong ; Ding, Xiaona ; Zhao, Bingzhu ; Yingpai, Zhaxi ; Chen, Hao ; Zhang, Taojie ; Yang, Chongfa ; Wang, Jine ; Li, Yang ; Zhao, Zhijie ; Yang, Yahua

Sheep ovarian granulosa cells (GCs) play a unique role in the ovary. Damage to GCs can affect the normal development of oocytes. The oxidative stress model was constructed by H₂O₂to study the biological changes. Specifically, pathological characteristic was assessed by immunohistochemistry (IHC), while signaling pathway was studied using western blot, quantitative RT-PCR, and immunofluorescence. Theresults showed that the oxidative damage model was successfully constructed by 200 μmol/LH₂O₂ for 12 h. NAC can protect the proliferation of GCs under H₂O₂-induced oxidative stress and reduce apoptosis. It can also promote the secretion of E₂ and P₄ by GCs and reduce the inflammatory response of GCs. NAC can enhance the expression of NRF2, PI3K and Akt. These findings suggest that NAC alleviates H₂O₂-induced oxidative stress injury through NRF2/PI3K/AKT signaling pathways. Provide ideas for studying the poor quality of mammalian oocytes.

2025-12-31·CANCER BIOLOGY & THERAPY

Long-term effects of neoadjuvant chemotherapy in variant histology locally advanced colon cancer: a propensity score-matched analysis

Article

作者: Wang, Zeshen ; Wang, Kuan ; Wang, Qiancheng ; Ju, Yuming ; Jin, Shiyang

PURPOSE:

Neoadjuvant chemotherapy (NAC) has proven valuable in treating locally advanced colon cancer (LACC) and is included as a treatment option for patients with clinical T4b colon cancer by the National Comprehensive Cancer Network. However, the long-term survival benefit of NAC in LACC remains debated, due to a lack of conclusive clinical trial results identifying the patients who would benefit most from NAC. This study aimed to assess the efficacy of NAC in patients with LACC based on histological subtype.

PATIENTS AND METHODS:

This retrospective study analyzed 3,709 patients with LACC who underwent curative resection at Harbin Medical University Cancer Hospital between 2014 and 2018. Patients were grouped into two groups: neoadjuvant chemotherapy (NAC) and adjuvant chemotherapy (AC) groups. Propensity score matching (PSM) was used to adjust for confounders, and survival outcomes of the two groups across different histological subtypes were evaluated using Kaplan-Meier (K-M) curves and log-rank tests.

RESULTS:

Patients with non-mucinous adenocarcinoma (NMAC) treated with NAC had a significantly improved 5-year OS rate (76.3% vs. 69.2%, p = .039) and DFS rate (67.2% vs. 60.1%, p = .041) compared with patients treated with AC. However, there was no significant difference in OS and DFS between the two treatment groups among patients with mucinous adenocarcinoma (MAC) and signet ring cell carcinoma (SRCC).

CONCLUSION:

In patients with LACC, the prognostic value of NAC varied by histology. NMAC may serve as a predictor of improved long-term survival benefit from NAC in these patients.

2025-12-31·JOURNAL OF INVESTIGATIVE SURGERY

Effects of Hsa-miR-4741/LILRB2 on Senescence of Nucleus Pulposus Cells and Their Prognostic Values in Lumbar Disc Herniation

Article

作者: Lin, Mingjian ; He, Zhendong ; Wang, Gang-Gang ; Zheng, Nan ; Guo, Xiu-Quan

BACKGROUND:

The incidence of lumbar disk herniation (LDH) is usually caused by lumbar disk degeneration. Surgery is a common treatment strategy for LDH, but it can recur, resulting in recurrent disk herniation (RDH).

PURPOSE:

To explore the predictive value of hsa-miR-4741 and LILRB2 in the prognosis of LDH surgery and the mechanism of nucleus pulposus senescence.

METHOD:

The ROC curves of RDH based on hsa-miR-4741 and LILRB2 were constructed to evaluate their predictive values in the prognosis of LDH surgery. Human nucleus pulposus cells (NPC) was treated by TNF-α to construct a cell senescence model, studying the senescence mechanism. Oxidative stress and senescence markers were detected after overexpression of hsa-miR-4741 and LILRB2 to evaluate their effects on the senescence of NPC. Dual luciferase assay and the transfection of hsa-miR-4741 mimics or inhibitor were used to investigate the targeted regulation of it to LILRB2.

RESULTS:

The combination of hsa-miR-4741 and LILRB2 showed higher accuracy in predicting the outcome of RDH (AUC = 0.9367), compared with a single molecule. Overexpression of hsa-miR-4741 enhanced TNF-α-induced oxidative stress and senescence, while LILRB2 overexpression had the opposite effect. Hsa-miR-4741 mimics attenuated the luciferase activity of NPC transfected with wt-LILRB2 vector and significantly down-regulated LILRB2 expression. In addition, the antioxidant NAC reversed the promotion of hsa-miR-4741 on NPC senescence.

CONCLUSION:

The combination of hsa-miR-4741 and LILRB2 was a good predictor of LDH prognosis. Hsa-miR-4741 promoted oxidative stress-induced NPC senescence by negatively regulating LILRB2.

437

项与乙酰半胱氨酸相关的新闻（医药）

2025-05-22

·药通社

国采信息有变，新增产品11个，附中选价格！

2025 未来医药新物种百强奖 FNS101 | 点击查看详情5月20日，国家组织药品联合采购办公室发布通知，国家组织药品集中采购部分中选药品信息变更的通知（第三批）。其中，新增受委托生产企业品种，4个：硝苯地平控释片、硝苯地平控释片、熊去氧胆酸胶囊、左卡尼汀注射液。新增中选产品规格、包装信息的品规，11个: 盐酸吡格列酮胶囊、琥珀酸美托洛尔缓释片、依折麦布片、左卡尼汀注射液、乙酰半胱氨酸颗粒、胞磷胆碱钠注射液、胞磷胆碱钠注射液、奥美沙坦酯氨氯地平片、奥美沙坦酯氢氯噻嗪片、盐酸伊伐布雷定片、重酒石酸去甲肾上腺素注射液。↓ 扫码加入药通社交流群 ↓投稿/企业合作/内容沟通：华籍美人（Ww_150525）

带量采购

2025-05-22

·药通社

终于！乙酰半胱氨酸注射液原研上市！！

2025 未来医药新物种百强奖 FNS101 | 点击查看详情5月21日，NMPA发布了大批药品批准件，多款产品获批上市，其中赞邦/上海精鼎医药的乙酰半胱氨酸注射液以5.1类获批，获批规格为3ml：300mg。赞邦这款原研产品在历经三年多时间，完成Ⅲ期临床后，终于上市了。依据赞邦获得的临床默示许可批件可推断，赞邦此次的获批适应症为：治疗浓稠粘液分泌物过多的呼吸道疾病如：急性支气管炎、慢性支气管炎及其病情恶化者、肺气肿、粘稠物阻塞症以及支气管扩张症。该适应症为国内首次上市。由于该品种的规格和适应症较多，较复杂，上市情况和过评情况可参考以下表格：目前国内乙酰半胱氨酸注射液已上市企业共4家，分别是民生、国润、海梦智森和汇宇。其中前期上市的三家规格均为20ml:4g，适应症：在综合治疗基础上用于肝衰竭早期治疗，以降低胆红素、提高凝血酶原活动度。但均未过评。四川海梦智森生物制药有限公司（国药准字H20183104）以补充申请方式进行一致性评价，已进入补充资料阶段。除以上三家外，汇宇是乙酰半胱氨酸注射液首家也是唯一一家过评的企业。2024年10月16日四川汇宇制药股份有限公司以3类仿制获批，视同通过，规格：30ml：6g。适应症：用于急性对乙酰氨基酚中毒解毒，用于预防或减轻其过量引起的肝脏损伤。相关文章：30过1？“乙酰半胱氨酸注射液”首家过评！！由于参比规格和适应症未在国内上市，此品种国内仿制已累计被驳回了21家，相关文章：1个月被CDE拒批5次？规格&适应症都不太可能批准！此次原研上市，或将迅速扭转该品国内仿制局面：图| 乙酰半胱氨酸注射液21家被驳回除四川海梦智森正在进行一致性评价外，乙酰半胱氨酸注射液还有8家企业在走仿制上市申请流程。注册分类均为仿制3类，但其中有两家企业的申报规格非参比规格，而是20ml:4g：江苏润恒和远大医药。5月21日发布的批准件还有多款药物顺利上市，海思科1类新药安瑞克芬注射液获批上市，适用于治疗腹部手术后的轻、中度疼痛，国内首个获批镇痛适应症的外周高选择性kappa阿片受体（KOR）激动剂。勃林格殷格翰的注射用替奈普酶获批上市，替奈普酶是一款新型溶栓药物，本次获批的适应症为治疗4.5小时内急性缺血性卒中。科伦新增两个重磅粉液双室袋产品，注射用头孢他啶/氯化钠注射液和注射用比阿培南/氯化钠注射液。回归到乙酰半胱氨酸注射液来看，在Zambon顺利在国内上市后，想申报呼吸系统疾病适应症的仿制企业可按照仿制4类提交上市申请，就看第一家申报的企业是谁了？前段时间的佩玛贝特原研上市时间与首家仿制受理时间相隔9天，创造了相隔时间最短的记录，就看此次会不会创造新纪录。↓ 扫码加入药通社交流群 ↓投稿/企业合作/内容沟通：华籍美人（Ww_150525）

上市批准一致性评价医药出海

2025-05-21

·维健医药

富露施®注射液在中国获批用于治疗浓稠粘液分泌物过多的呼吸道疾病

• 富露施®注射液是目前中国市场上首个且唯一获批用于治疗浓稠粘液分泌物过多呼吸道疾病的乙酰半胱氨酸注射剂型产品1• 除溶痰、排痰、抑痰外，还兼具抗炎、抗氧化及抑制细菌和病毒定植、复制等多重肺保护机制• 临床数据显示，富露施®注射液不仅能降低痰液黏度、改善排痰困难，还显著改善重症患者预后，缩短住院时间，降低死亡率• 疗效确切、安全性高，为不能口服、不能雾化的危重患者提供了新的治疗选择2025年5月21日，香港维健医药集团（简称“维健医药”）宣布，中国国家药品监督管理局（NMPA）已正式批准由意大利赞邦制药集团原研的富露施®注射液（英文名：Fluimucil ®, 通用名：乙酰半胱氨酸注射液）用于治疗浓稠粘液分泌物过多的呼吸道疾病如：急性支气管炎、慢性支气管炎及其病情恶化者、肺气肿、粘稠物阻塞症以及支气管扩张症。祛痰是呼吸系统疾病治疗中的重要环节。痰液的过度分泌和黏稠化是多种呼吸道疾病的常见症状，如急性支气管炎、慢性支气管炎急性加重、肺气肿、支气管扩张症等。黏稠的痰液不仅会阻塞呼吸道，导致呼吸困难，还可能继发感染，加重病情。因此，祛痰治疗对于改善患者症状、恢复肺功能、预防并发症具有重要意义。祛痰药物通过降低痰液的黏稠度，促进痰液排出，帮助患者恢复正常的呼吸功能，是呼吸道疾病综合治疗中不可或缺的一部分。本次获批基于中国III期临床试验研究结果，III期临床证明富露施®注射液疗效确切，对呼吸道疾病合并黏液高分泌的患者安全且耐受性好；与安慰剂相比，使用富露施®注射液后患者在痰液粘稠度和咳痰难度方面均明显改善2。香港维健医药集团董事长王威先生表示：“富露施®注射液在中国的获批为患者提供了全新的治疗选择，尤其是为临床上无法口服或雾化的重症患者带来了切实有效的治疗方案。作为一家始终坚持‘以患者为先’的公司，凭借全球视野，我们积极引进原研品牌和创新治疗方案，切实满足患者的需求。维健医药在呼吸领域深耕多年，此次获批标志着我们在这一领域迈出了更为坚实的一步，为中国患者带来了国际领先的治疗选择。未来，我们将继续推动更多创新药在中国本地化应用，为‘健康中国2030’宏伟目标的实现贡献力量。”富露施®注射液自上市以来，凭借出色的疗效和良好的安全性，已被广泛应用于全球多个国家和地区。因其抗氧化作用，富露施®注射液已被意大利新型冠状病毒感染（COVID-19）治疗指南推荐用于COVID-19的治疗。同时，它在祛痰与抗氧化应激的相关研究结果正持续发布，进一步证明其在临床中的广泛应用潜力。关于富露施®注射液富露施®注射液是意大利赞邦制药集团旗下产品。2025年2月24日，维健医药与意大利赞邦制药集团达成战略合作，获得富露施®注射液在中国大陆市场的独家商业化权益。富露施®注射液（乙酰半胱氨酸注射液）是一种具有多重作用机制的祛痰药物。其主要成分乙酰半胱氨酸（化学名：N-乙酰-L-半胱氨酸，简称 NAC）是一种合成的氨基酸衍生物，能够有效分解痰液中的黏蛋白3，降低痰液的黏稠度，从而促进痰液排出。此外，NAC还具有抗氧化和抗炎作用，能够有效缓解呼吸道炎症，保护肺组织免受氧化损伤4,5。自全球上市以来，凭借其卓越的祛痰效果和良好的安全性，富露施®注射液已被广泛应用于临床。其祛痰机制主要通过以下两种方式实现：一是直接断裂痰液中黏蛋白的二硫键，使黏蛋白解聚，降低痰液黏度，从而更易于咳出3；二是加强气道纤毛的摆动及清除能力，促进痰液的生理运输6。临床研究表明，富露施®注射液能够有效改善患者的痰液黏稠度和咳痰困难程度，且耐受性良好2。关于富露施®注射液临床III期试验富露施®注射液在中国的III期临床试验评估了该产品在中国人群中的疗效和安全性。研究结果表明，富露施®静脉注射液（600mg，每日两次）在痰液粘稠度评分和咳痰难度评分方面，从基线到第7天的变化显著优于安慰剂。此外，富露施®注射液起效快，疗效确切，对急性和慢性呼吸道疾病合并粘液高分泌的患者安全且耐受良好2。关于维健医药香港维健医药集团成立于2006年，是一家总部位于中国香港的综合性全产业链生物制药企业。公司聚焦自有工业产品、CSO产品、特药产品三大板块，专注于创新药物的开发、生产与商业化。维健医药始终秉持“患者为先”的初心，致力于为罹患心肾疾病、血液肿瘤、胃肠疾病、呼吸和抗感染疾病、罕见病及其他治疗需求未被充分满足的患者提供突破性疗法和创新医疗解决方案，旨在切实改善患者的生活质量。集团立足中国，积极拓展亚洲及其他国际市场，致力于构建医疗健康生态体系，推动行业创新，满足患者日益增长的治疗需求。如需了解更多信息，请访问公司官网：www.winhealth.hk 。参考文献As of April 2025, the data source: Ding Xiang Yuan database.Tang W, , et al. Intravenous N-acetylcysteine in respiratory disease with abnormal mucus secretion. Eur Rev Med Pharmacol Sci. 2023 Jun;27(11):5119-5127. doi: 10.26355/eurrev_202306_32628.Davis SS, et al. The effect of sulphydryl compounds and cross linking agents on the viscous and viscoelastic properties of mucus.Biorheology. 1975 Jun;12(3-4):225-32. doi: 10.3233/bir-1975-123-415.Sadowska AM, et al. The interrelationship between markers of inflammation and oxidative stress in chronic obstructive pulmonary disease: modulation by inhaled steroids and antioxidant. Respir Med. 2005 Feb;99(2):241-9. doi: 10.1016/j.rmed.2004.07.005. Szkudlarek U, et al. D. Effect of inhaled N-acetylcysteine on hydrogen peroxide exhalation in healthy subjects. Pulm Pharmacol Ther. 2004;17(3):155-62. doi: 10.1016/j.pupt.2004.01.007.Rogers DF. Mucoactive agents for airway mucus hypersecretory diseases. Respir Care. 2007 Sep;52(9):1176-1193.

临床3期申请上市上市批准临床结果

100 项与乙酰半胱氨酸相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00221	乙酰半胱氨酸	V03AB23 S01XA08 R05CB01	DB06151

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
支气管炎	中国	精鼎医药研究开发（上海）有限公司	2025-05-13
嵌甲	日本	Maruho Co., Ltd.	2023-03-27
对乙酰氨基酚过量	澳大利亚	Pfizer Australia Pty Ltd.	2006-07-17
慢性阻塞性肺疾病	中国	江苏吉贝尔药业股份有限公司	1985-01-01
哮喘	日本	Sannova KK	1965-01-05
支气管扩张	日本	Sannova KK	1965-01-05
慢性支气管炎	日本	Sannova KK	1965-01-05
囊性纤维化	日本	Sannova KK	1965-01-05
喉炎	日本	Sannova KK	1965-01-05
咽炎	日本	Sannova KK	1965-01-05
肺炎	日本	Sannova KK	1965-01-05
肺气肿	日本	Sannova KK	1965-01-05
肺结核	日本	Sannova KK	1965-01-05
药物性肝损伤	美国	Apothecon LLC	1963-09-14
肝损伤	美国	Apothecon LLC	1963-09-14

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
急性支气管炎	临床3期	中国	Zambon Switzerland Ltd.	2019-06-21
急性支气管炎	临床3期	中国	Zambon SpA	2019-06-21
特发性肺纤维化	临床3期	比利时	Zambon SpA	2000-03-01
特发性肺纤维化	临床3期	法国	Zambon SpA	2000-03-01
特发性肺纤维化	临床3期	德国	Zambon SpA	2000-03-01
特发性肺纤维化	临床3期	意大利	Zambon SpA	2000-03-01
特发性肺纤维化	临床3期	荷兰	Zambon SpA	2000-03-01
特发性肺纤维化	临床3期	西班牙	Zambon SpA	2000-03-01
特发性肺纤维化	临床3期	英国	Zambon SpA	2000-03-01
普通感冒	临床2期	加拿大	Novartis AG	2015-01-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04732000 (CTgov)	临床2期	应激氧化 \| 术后疼痛	30	N-acetyl cysteine (N-acetyl Cysteine)	顧齋艱觸鏇壓鏇鏇廠願(獵鏇積繭窪糧艱鹽鏇壓) = 餘願願壓鬱膚夢積膚願膚積網壓鏇夢膚範鹽觸 (簾鬱廠製壓壓積積遞鑰, 選鬱淵齋顧築窪蓋糧顧 ~ 襯糧築顧鏇繭構遞繭簾) 更多	-	2025-04-30
				Normal saline (Normal Saline)	顧齋艱觸鏇壓鏇鏇廠願(獵鏇積繭窪糧艱鹽鏇壓) = 鹽構顧鹹蓋膚製觸觸鑰膚積網壓鏇夢膚範鹽觸 (簾鬱廠製壓壓積積遞鑰, 鬱顧糧鬱鏇壓繭憲築醖 ~ 製構鬱蓋製選襯願觸獵) 更多
AACR2025	N/A	血液肿瘤 H3 \| γ-H2A.X \| GSH	-	N-acetyl-L-cysteine (NAC)	繭鹹鑰窪窪襯夢憲廠窪(獵構獵顧選憲範獵簾繭) = 願蓋膚齋蓋構鬱觸壓夢簾網鏇遞廠襯鑰鏇廠繭 (顧願齋餘廠鏇鏇齋積壓 )	积极	2025-04-29
				Psammaplin A (PsA)	繭鹹鑰窪窪襯夢憲廠窪(獵構獵顧選憲範獵簾繭) = 鑰鏇餘窪艱遞築蓋顧鑰簾網鏇遞廠襯鑰鏇廠繭 (顧願齋餘廠鏇鏇齋積壓 )
NCT00585559 (CTgov)	临床3期	颅内动脉瘤1 \| 颅内血管痉挛	44	N-acetylcysteine (N-acetylcysteine IV Infusion at 0.5 gm Hourly)	廠糧簾夢鏇膚繭鑰選齋(襯築選網夢廠窪獵網淵) = 壓夢選願齋網憲餘選範遞廠築廠糧網憲積願願 (觸積膚鹹衊願夢齋憲壓, 顧遞積選襯餘襯壓繭積 ~ 獵襯襯窪積膚醖醖襯醖) 更多	-	2025-04-18
				Placebo+N-acetylcysteine (Placebo for N-acetylcysteine IV Infusion at 0.5 gm Hourly)	廠糧簾夢鏇膚繭鑰選齋(襯築選網夢廠窪獵網淵) = 糧築壓鹽獵壓鬱鏇觸鑰遞廠築廠糧網憲積願願 (觸積膚鹹衊願夢齋憲壓, 鹹鏇構壓窪繭顧蓋廠鏇 ~ 襯廠鑰壓憲網範簾網繭) 更多
NCT03306979 (CTgov)	临床2期	认知功能障碍	60	N Acetylcysteine (N-acetylcysteine)	餘鹽遞淵觸繭選壓網壓(蓋夢艱範鏇艱積衊糧鹽) = 積鹽遞鹹範窪顧鹽醖遞鑰顧憲壓蓋鏇鬱鹽獵廠 (衊鑰齋鹽衊願窪窪顧鹽, 積鬱憲鹽鏇鬱簾窪築繭 ~ 獵壓醖鏇構鑰憲窪製餘) 更多	-	2025-03-26
				Placebo oral capsule (Placebo)	餘鹽遞淵觸繭選壓網壓(蓋夢艱範鏇艱積衊糧鹽) = 觸簾構願鑰醖鬱糧夢範鑰顧憲壓蓋鏇鬱鹽獵廠 (衊鑰齋鹽衊願窪窪顧鹽, 鑰蓋鏇壓齋繭壓艱醖鬱 ~ 糧餘淵糧鏇鏇窪齋鹽簾) 更多
NCT04766450 (Pubmed \| Diabetol Metab Syndr)	临床4期	糖尿病周围神经病变辅助 Glutathione peroxidase \| NRF-2 \| TNF	-	N-acetyl cysteine 2400 mg/day	壓鹽鬱選鬱鬱選壓觸製(鏇願齋憲網構衊廠齋廠) = 襯製鏇膚蓋鹹壓淵膚顧膚製壓構糧顧蓋鹽選積 (簾齋蓋廠淵繭糧遞鹹壓 ) 更多	积极	2025-03-04
NCT03707951 (CTgov)	临床2期	酒精使用障碍	126	N-acetylcysteine (N-acetylcysteine)	簾夢憲餘範構觸鹽獵壓(憲齋壓繭艱鹽夢衊選壓) = 獵顧糧膚願醖鹹鑰顧齋衊窪鏇鏇壓衊簾觸衊窪 (淵簾襯願選襯廠鏇築繭, 28.3) 更多	-	2025-01-08
				Placebo oral capsule (Placebo)	簾夢憲餘範構觸鹽獵壓(憲齋壓繭艱鹽夢衊選壓) = 構糧淵構糧鏇鹹獵鹽觸衊窪鏇鏇壓衊簾觸衊窪 (淵簾襯願選襯廠鏇築繭, 43.1) 更多
Pubmed 人工标引	N/A	慢性阻塞性肺疾病	91,546	N-acetylcysteine (NAC) users	鏇醖鹽淵齋鹹窪蓋餘製(蓋醖餘醖齋鬱壓簾壓膚) = 觸蓋壓網衊餘齋鏇網網廠蓋鹽廠衊艱網簾範遞 (積襯壓醖鹹膚淵遞衊憲 )	积极	2025-01-01
				Non-NAC users	鏇醖鹽淵齋鹹窪蓋餘製(蓋醖餘醖齋鬱壓簾壓膚) = 窪衊鬱構艱艱鹹餘鹽製廠蓋鹽廠衊艱網簾範遞 (積襯壓醖鹹膚淵遞衊憲 )
NCT03055377 (CTgov)	临床2/3期	大麻戒断	192	N-Acetyl Cysteine (N-acetylcysteine)	鑰遞簾選餘蓋鏇壓蓋築 = 憲艱餘鹽鹽壓觸願顧積憲蓋製糧製鹹簾夢鹽願 (築繭淵襯範構願鹹築窪, 鹹鏇積觸窪鹽鹹觸鑰鏇 ~ 糧構鏇網鹹積糧餘廠鹹) 更多	-	2024-12-17
				Placebo oral capsule (Placebo)	鑰遞簾選餘蓋鏇壓蓋築 = 窪蓋鹹艱簾繭夢淵夢築憲蓋製糧製鹹簾夢鹽願 (築繭淵襯範構願鹹築窪, 範鏇願憲夢餘簾醖餘鏇 ~ 醖鹽艱選鑰艱鹽夢醖鹽) 更多
DEEPSARC (ESMO_ASIA2024)	N/A	软组织肉瘤辅助 \| 新辅助	8,331	Adjuvant Chemotherapy (AC)	衊衊夢蓋膚艱獵獵鏇糧(醖範顧繭壓窪鹹窪夢網) = 網獵遞蓋壓蓋衊廠糧遞齋廠鏇鹽廠壓蓋廠膚鏇 (廠餘壓醖壓築壓餘選鹽, 47 ~ 54)	不佳	2024-12-07
				Neoadjuvant Chemotherapy (NAC)	衊衊夢蓋膚艱獵獵鏇糧(醖範顧繭壓窪鹹窪夢網) = 簾築繭遞壓築範餘餘壓齋廠鏇鹽廠壓蓋廠膚鏇 (廠餘壓醖壓築壓餘選鹽, 61 ~ 64)
NCT00558142 (CTgov)	临床4期	肾脏疾病	107	placebo+Acetylcysteine (Healthy Volunteers, no Contrast)	鏇築醖選積艱構艱窪鏇(遞膚艱鬱觸願製鹽鹽願) = 顧壓鑰醖遞鏇餘遞廠鏇壓淵夢醖簾糧顧鹹觸憲 (鬱衊顧齋窪衊鏇衊淵淵, 築窪觸簾築窪鏇築醖淵 ~ 膚艱遞夢製鬱膚廠構淵) 更多	-	2024-09-19
				placebo+Acetylcysteine (Volunteers With CKD III, no Contrast)	鏇築醖選積艱構艱窪鏇(遞膚艱鬱觸願製鹽鹽願) = 餘夢鏇餘積淵夢齋獵獵壓淵夢醖簾糧顧鹹觸憲 (鬱衊顧齋窪衊鏇衊淵淵, 觸選襯壓艱齋衊鑰艱糧 ~ 膚襯網齋積蓋簾衊積壓) 更多